Emyria Strengthens NSW Clinical Network Ahead of Sydney Expansion
Emyria Limited (ASX: EMD), a provider of evidence-based mental health treatments, has completed the training of its first New South Wales (NSW) clinical cohort in preparation for the launch of its inaugural Sydney-based Empax clinic. The training program included 25 therapists and six psychiatrists, expanding Emyria’s national network to more than 100 trained and contracted clinicians across Western Australia, Queensland, Victoria, and now NSW. The initiative marks a significant milestone in the company’s strategy to broaden access to innovative mental health therapies across Australia.
The newly trained clinicians will support operations at the Sydney clinic, which is scheduled to open in Q3 CY2026 at Matilda Nepean. Alongside workforce development, Emyria has secured medication supply and is finalising clinic fit-out requirements, keeping the project aligned with planned milestones.
The expansion comes as demand for mental health services continues to rise in NSW, Australia’s largest addressable patient market. Emyria believes the strengthened workforce and upcoming clinic opening will enhance access to emerging evidence-based therapies for patients with complex mental health conditions while supporting the company’s national growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Emyria Strengthens NSW Clinical Network Ahead of Sydney Expansion
Emyria Limited (ASX: EMD), a provider of evidence-based mental health treatments, has completed the training of its first New South Wales (NSW) clinical cohort in preparation for the launch of its inaugural Sydney-based Empax clinic. The training program included 25 therapists and six psychiatrists, expanding Emyria’s national network to more than 100 trained and contracted clinicians across Western Australia, Queensland, Victoria, and now NSW. The initiative marks a significant milestone in the company’s strategy to broaden access to innovative mental health therapies across Australia.
The newly trained clinicians will support operations at the Sydney clinic, which is scheduled to open in Q3 CY2026 at Matilda Nepean. Alongside workforce development, Emyria has secured medication supply and is finalising clinic fit-out requirements, keeping the project aligned with planned milestones.
The expansion comes as demand for mental health services continues to rise in NSW, Australia’s largest addressable patient market. Emyria believes the strengthened workforce and upcoming clinic opening will enhance access to emerging evidence-based therapies for patients with complex mental health conditions while supporting the company’s national growth strategy.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au